Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility

The Journal of Antimicrobial Chemotherapy
Rubaiyea FarrukeeAeron C Hurt

Abstract

The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a widely used neuraminidase inhibitor (NAI) antiviral drug, may have reduced effectiveness against influenza B viruses. Therefore, it is important to study the effect of neuraminidase mutations in influenza B viruses that may further reduce NAI susceptibility, and to determine whether these mutations have the same effect in the two lineages of influenza B viruses that are currently circulating (B/Yamagata-like and B/Victoria-like). We characterized the effect of 16 amino acid substitutions across five framework residues and four monomeric interface residues on the susceptibility to four different NAIs (oseltamivir, zanamivir, peramivir and laninamivir). Framework residue mutations E117A and E117G conferred highly reduced inhibition to three of the four NAIs, but substantially reduced neuraminidase activity, whereas other framework mutations retained a greater level of NA activity. Mutations E105K, P139S and G140R of the monomeric interface were also found to cause highly reduced inhibition, but, interestingly, their effect was substantially greater in a B/Victoria-like neuraminidase than in a B/Yamagata-like neuramini...Continue Reading

References

Oct 21, 1998·The Journal of Infectious Diseases·L V GubarevaR G Webster
Jan 19, 1999·Scientific American·W G LaverR G Webster
Aug 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Erich HoffmannGeorge Kemble
Oct 22, 2002·Journal of Virology·David JacksonWendy S Barclay
Nov 16, 2004·Journal of Virology·Jonathan A McCullersAmy R Iverson
Jan 25, 2005·The Journal of Antimicrobial Chemotherapy·David JacksonThomas Zürcher
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Naoki KawaiSeizaburo Kashiwagi
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·Vasiliy P MishinLarisa V Gubareva
Feb 16, 2006·The Journal of Infectious Diseases·Michael G IsonFrederick G Hayden
Jul 14, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Naoki KawaiSeizaburo Kashiwagi
Nov 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mariana BazGuy Boivin
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Norio SugayaYoshihiro Kawaoka
Apr 5, 2007·JAMA : the Journal of the American Medical Association·Shuji HatakeyamaYoshihiro Kawaoka
May 23, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Naoki KawaiSeizaburo Kashiwagi
Dec 7, 2007·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Vanessa EscuretOlivier Ferraris
Dec 7, 2007·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Olivier Ferraris, Bruno Lina
Mar 29, 2008·Methods in Molecular Biology·Mary Lea Killian
May 28, 2008·Journal of Molecular Evolution·Rubing Chen, Edward C Holmes
Jun 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Norio SugayaKeiko Mitamura
Oct 9, 2009·Antiviral Therapy·Masato TashiroUNKNOWN Neuraminidase Inhibitor Susceptibility Network
Sep 8, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Santtu HeinonenTerho Heikkinen
Nov 5, 2010·The Pediatric Infectious Disease Journal·Silvana CarrRobert G Webster
Nov 22, 2011·Emerging Infectious Diseases·Katrina SleemanLarisa V Gubareva
Mar 1, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hideyuki IkematsuSeizaburo Kashiwagi
Apr 27, 2012·Journal of Clinical Microbiology·Rachel R HigginsJonathan B Gubbay
Jan 19, 2013·American Journal of Public Health·W Paul GlezenJohn Oxford
Mar 27, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Seiichiro FujisakiTakato Odagiri
Apr 12, 2013·Influenza and Other Respiratory Viruses·Margaret Okomo-AdhiamboLarisa V Gubareva
Jul 20, 2013·American Journal of Public Health·Roman PabayoIchiro Kawachi
May 6, 2014·The Journal of Infectious Diseases·Vanessa EscuretBruno Lina

❮ Previous
Next ❯

Citations

Sep 22, 2015·Viruses·Timothy C M LiNelson Lee
Jan 26, 2016·The Tohoku Journal of Experimental Medicine·Hiroki KondoReiko Saito
Aug 21, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Z JenningsD E Dwyer
Aug 26, 2016·Drug Discoveries & Therapeutics·Siriwan CharyasriwongNobuyuki Kobayashi
Sep 12, 2015·Future Microbiology·Carolien E van de SandtRory D de Vries

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.